Eloro Intersects 129.65 g Ag eq/t over 300.75m in the Mineralized Envelope of the Santa Barbara Breccia Pipe at the Iska Iska Silver-Tin Polymetallic Project, Potosi Department, Bolivia

ELO.V, Eloro, 321gold.com, Bob Moriarty, Bolivia, Iska Iska property,
Table 1

Eloro Resources Ltd. (TSX-V: ELO; OTCQX: ELRRF FSE: P2QM) (“Eloro”, or the “Company”) is pleased to provide an update on its Iska Iska silver-tin polymetallic project in Potosi Department, southern Bolivia. To date, the Company has completed 46 diamond drill holes totalling 22,398.9 metres (m) to test major target areas at Iska Iska. This press release reports drilling results from four (4) additional holes which tested the mineralized envelope of the Santa Barbara Breccia Pipe (“SBBP”) and the central-southern part of the Central Breccia Pipe (“CBP”). To date, every drill hole that has been assayed has returned multiple reportable mineralized intercepts. Currently three drill rigs are in operation at Iska Iska. One surface drill rig is completing first pass drilling of the major Porco (South) Target. The second surface drill is currently cleaning out drill holes on the SBBP radial platform for the planned downhole induced polarization/resistivity (IP/RES) survey then will be moved to test the gap area between the Central and Porco Breccia Pipes. The third drill, an underground rig, is testing the northeast part of SBBP and its mineralized envelope. This drill will shortly be moved to a new drill bay recently completed on the west end of the Santa Barbara adit. Figure 1 is a geological plan map showing locations of drill holes and an updated geological interpretation. Figure 2 is a more detailed geological plan map of the SBBP and northern CBP areas showing the magnetic low target to the northwest of the SBBP where drilling is planned (see press release June 7, 2021 for an overview of the magnetic results). Table 1 provides significant drilling results and Table 2 lists holes completed with assays pending as well as holes in progress in the three major target areas. Highlights are as follows: read more

DehydraTECH(TM) – Enabled Consumer Products Now Available in Over 7,000 Stores

Lexaria’s technology empowers brands nationwide in stores including Albertsons, Hudson News, and many more
Lexaria Bioscience

Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce that its DehydraTECHTM technology has been embraced by consumer brands now available for sale in over 7,000 stores across the US. read more

Tocvan Drills 15.3 meters of 1.1 g/t Au in New 4-Trench Extension Defines new mineralized trend over a 500 meter strike at Pilar

CSE:TOC, TocVan Ventures, gold, mexico

Tocvan Ventures Corp. (CSE:TOC) (CNSX:TOC.CN) (“Tocvan” or the “Corporation”) is pleased to announce results for the next four drill holes from its Phase II drill program (the “Program”) at the Pilar Gold-Silver Project in Sonora, Mexico. A Phase II drill program was completed in June with over 3,500 meters of reverse circulation (RC) drilling in twenty (20) drill holes. Results for four drill holes from the 4-Trench target area are included in this release, highlighted by drill hole JES-21-53 which returned 15.3 meters at 1.1 g/t Au. The results from 4-Trench have defined a new mineralized trend 500 meters long adjacent to the established Main Zone (Figure 1). Three (3) drill holes from new target areas are pending results. read more

Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2

Additionally, second patent award received in Japan
Lexaria Bioscience

Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce that dosing has been completed in its second human clinical study of 2021. read more

NexGen Announces Commencement of 2021 Field and Regional Exploration Drilling Programs at the Rook I Property

T.NXE, NexGen, uranium
Figure 1: Rook I Property 2021 Exploration Target Areas (CNW Group/NexGen Energy Ltd.)

NexGen Energy Ltd. (“NexGen” or the “Company”) (TSX: NXE) (NYSE: NXE) (ASX: NXG) is pleased to announce commencement of field programs focused on detailed geotechnical site confirmation studies on the Project and regional exploration drilling at the 100% owned, Rook I property (the “Property”), in the Athabasca Basin, Saskatchewan. read more

Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy

All objectives evaluating DehydraTECH™ drug delivery platform successfully achieved
Lexaria Bioscience
  read more

Lexaria’s DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3

Possible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side Effects
Lexaria Bioscience
DrugCmax* % Improvement
(ng/mL)
Control
(ng/mL)
AUClast** % Improvement
(hr∙ng/mL)
Control
(hr∙ng/mL)
Colchicine31.97
91%
(p=0.0005)
16.73104.43
167%
(p=0.0028)
38.97

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. read more

Gran Colombia Announces Second Quarter 2021 Production and Webcast; Provides Details of Forthcoming Repayment of Its Gold Notes; Declares Monthly Dividend to be Paid on August 16, 2021

Gran Colombia Gold Corp. (TSX: GCM; OTCQX: TPRFF) announced today that it produced a total of 16,789 ounces of gold at its Segovia Operations in June 2021 bringing the total gold production for the second quarter of 2021 to 52,198 ounces compared with 44,377 ounces from Segovia in the second quarter of 2020. The Company also produced 54,573 ounces of silver at Segovia in the second quarter of 2021, up from 41,342 ounces of silver in the second quarter last year. For the first half of 2021, Segovia’s gold and silver production totalled 101,256 ounces and 111,888 ounces, respectively, up from 94,723 ounces of gold and 87,260 ounces of silver in the first half of 2020. read more

Lexaria Completes Successful Antiviral Drug Molecular Characterization Study with Canada’s National Research Council

VIRAL-MC21-1 Demonstrates Stability of DehydraTECH™-Enabled Antiviral Drugs
Lexaria Bioscience

Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce results from its antiviral drug molecular characterization study VIRAL-MC21-1 recently completed by Canada’s premier federally funded research organization, the National Research Council (“NRC”). read more

Magazine Plus by WEN Themes